Polyanydride Nanoparticles: A Drug delivery vehicle to kill intracellular pathogens by Lueth, Paul
Retrospective Creative Components Iowa State University Capstones, Theses andDissertations
2017
Polyanydride Nanoparticles: A Drug delivery
vehicle to kill intracellular pathogens
Paul Lueth
Follow this and additional works at: https://lib.dr.iastate.edu/rcc
Part of the Medicine and Health Sciences Commons
This Creative Component is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State
University Digital Repository. It has been accepted for inclusion in Retrospective Creative Components by an authorized administrator of Iowa State
University Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Lueth, Paul, "Polyanydride Nanoparticles: A Drug delivery vehicle to kill intracellular pathogens" (2017). Retrospective Creative
Components. 58.
https://lib.dr.iastate.edu/rcc/58
POLYANYDRIDE NANOPARTICLES: A 
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Overview 
•Introduction to IGS 
•VMPM 
• IMBIO 
•CHEM E 
•Project Outline 
•Key Observations, Results, Conclusion 
•Future Plans 
 
DESCRIPTION 
 Available to graduate students who wish to 
have a more diversified program of advanced 
study than generally permitted for students 
who specialize in a single subject 
 Program is open to any qualified graduate 
student, who wish to improve their subject 
matter competence in more than one 
discipline. 
  
COURSEWORK 
 Allowed to take courses in three different 
graduate subject matter areas 
 Each subject contributing a minimum of nine 
(9) semester credits toward the 35 semester 
graduate credits required for the degree 
Interdisciplinary Graduate Studies Program 
 
 NON-THESIS OPTION 
 A creative component is required in which 
the student demonstrates independent 
creativity such as a written report of 
laboratory, field or library research, a 
project in fine arts, or some other original 
contribution. 
 The student, in consultation with his/her Program of Study Committee, will decide on the choice 
of option (i.e., thesis or non-thesis). The Program of Study Committee also aids the student in 
planning a program of study, selecting appropriate courses, and determining foreign language 
requirements, if applicable. 
Interdisciplinary Graduate Studies Program 
 
Interdisciplinary Graduate Studies Program 
 
VMPM IMBIO 
CHEM E 
Interdisciplinary Graduate Studies Program 
 
PATHOGEN HOST 
THERAPY KILLING SAFETY 
DISEASE 
Brucellae 
 
 Gram Negative 
 Coccobacillus 
 Faculative Intracelluar 
Pathogens: 
 10 Species 
Species 
Species Biovar/Seravar Natural Host Human Pathogen 
B. melitensis species Goat, sheep yes 
B. abortus 1-6,9 Cattle, bison, buffalo yes 
B. suis 1, 2, 3  Swine yes 
4 European hares Yes 
5 Reindeer, caribou yes 
B. canis none Dogs, other canids yes 
B. ovis none Sheep no 
B. neotomae none Rodents no 
B. maris Marine mammals Yes(?) 
B. pinnipediae 
B. cetaceae(?) 
CENTER FOR FOOD SECURITY AND PUBLIC HEALTH, IOWA STATE UNIVERSITY, 2012 
Human Transmission 
 Rarely Fatal 
 Not transmissible from person to 
person 
 Zoonotic 
 Highly infection through aerosol 
 10-100 bacteria for infection 
 Conjuctiva, skin lesions, contact 
with infectious tissue, ingestion of 
unpasteurized dairy 
  
http://www.vet.uga.edu/vpp/archives/ivm/ENG/zoonoses/domestic/images/brucella_img02.jpg 
Brucellae 
 
 Symptoms in Humans 
 Undulating Fever 
 Headache 
 Anorexia 
 Complications include 
endocarditis, meningitis, 
arthritis 
Brucella 
 
 Treatement 
 Daily Combination of 
Doxycycline & Rifampin 
 Regiment 6-8 weeks 
 Relapse 
 No Vaccine for Human 
Brucellosis 
Prevention  
•Animal Vaccines 
•Avoid direct contact with visibly 
sick animals 
•Wear eye protection and gloves 
when handling carcasses 
•Do not drink unpasteurized 
milk 
  
Brucellae 
 
 Biological Threat 
 CDC Category B Biological Threat 
Agent 
◦Debilitating Symptoms 
◦Significant Morbidity 
◦Relapse of Infection 
◦Lack of Human Vaccine 
pH=6.5 
Brucellae 
 
 Virulence Factors 
 Intracellular nice 
 LPS very little endotoxicity & poor inducer of cytotoxic 
mediators 
 Smooth O-chain are resistant to serum & complement, enter 
via lipid rafts 
 Type IV Secretion System  
 Cyclic β-1,2-glucans 
 Prevents Apoptosis 
 (2,3-DHBA) & 2,3-DHBA-based siderophore brucebactin 
(Bellaire et al, 2003). 
  
  
  
pH=4.5 
pH=4.0 
pH=6.5 
Lamp-1 
Cathepsin D 
pH=4.5 
pH=4.0 
EEA-1 
Rab5 
Vacuolar ATPase 
pH=6.5 
Rab7 

pH=6.5 
Brucella Host Cellular Immune Response 
 Effective Response requires CMI 
 Cell-Mediated Response  
◦ TH1 response 
◦ Activate Macrophages 
 Immunity is based on IFN-γ  
◦ Controlled by IL-12 and TNF-α 
 ROI & NO contribute to Control 
  
Drug Delivery 
“refers to approaches, formulations, 
technologies, and systems for transporting a 
pharmaceutical compound in the body as 
needed to safely achieve its desired therapeutic 
effect.” 
 
http://www.reference.md/files/D016/mD016503.html 
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Controlled Drug Delivery 
Drug Delivery 
Must stabilize drug  
 Drug must be bioactive.  
 Therapeutic drugs (proteins), prone to deactivation (synthesis) 
 Proteins, in soluble form, may lose their functional properties (in vivo)  
Administer drug at a concentration  
 necessitates therapy  
 precludes toxicity 
 Drug to be released in a controlled, and sustained manner. 
Material that encapsulates and delivers drug should be biodegradable 
Biodegradable Polymers 
 Encapsulates drug 
 Safely degrade 
 Excellent candidates for controlled release 
 Versatility in degradation mechanism 
 Two main classes: Polyanhydrides and 
Polyesters 
 Two degradation mechanism 
 
  
What can be hydrolyzed? 
1. Anhydrides 
 
 
2. Esters 
 
 
3. Carbonates 
 
 
4. Amide 
 
Fast 
Slow 
Polyesters vs. Polyanhydrides 
 Both approved for use in humans 
 Both have tailorable release rates 
 Polyesters: bulk eroding, acidic degredation products 
 Polyanhydrides: surface eroding, very hydrophobic 
C O C
O O
Water-labile 
• Anhydride bond 
• Hydrolytically unstable 
• Degrades into two 
carboxylic acid groups 
• Suitable for drug delivery 
systems 
• Gliadel® 
• Surface erodible 
 
 
 
Polyanhydrides 
Domb, Amselem, Langer, and Maniar, in Biomedical Polymers Designed-to-Degrade Systems (1993) 
Commercialized Controlled 
Release Formulations 
Brand Name Application 
Release 
time 
Delivery 
route 
Anti-tumor Weeks Implant 
Allergy 1 Day Oral 
Contraceptive 1 Month Injection 
Anti-
depressant 
1 Week Oral 
Bulk Erosion 
 Hydrophilic backbone 
 Porous 
 Allow water to diffuse through 
surface 
 High porosity 
 Fast process 
Modified 
1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) 
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1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) 
 Maximum Desired Level 
Minimum Effective Level 
R
el
ea
se
 R
at
e
 
Time 
Dose 1 
O
O
O
O
O
n
 
O
O
d
c(
t)
 
d
t 
Surface Erosion 
 Surface Erosion 
 Hydrophobic polymers 
 Prevent water from penetrating 
interior 
 Limited porosity 
 Slow process 
Hydrophobic anhydride monomer  
1,6-bis(p-carboxyphenoxy) hexane (CPH) 
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Hydrophobic anhydride monomer  
1,6-bis(p-carboxyphenoxy) hexane (CPH) 
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Erosion Mechanism of CPTEG:CPH 
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Poly(CPTEG) Poly(CPH)
Polymers exhibit distinct erosion profiles that can be controlled by tailoring copolymer composition 
Torres, Vogel, Mallapragada, and Narasimhan, J. Biomed. Mater. Res. (2006) 
 Polymer degradation 
◦ Bulk erosion (e.g., CPTEG) 
◦ Surface erosion (CPH & SA) 
 Drug/protein release 
 Protein/antigen stabilization 
◦ Structure 
◦ Function 
 Immunomodulatory vaccines 
◦ Single dose 
◦ Efficacious immune responses 
 
Shen et al, J. Contr. Rel. (2002)     Determan et al, J. Contr. Rel. (2004)      Kipper et al, J. Biomed. Mater. Res. (2006)c 
Chemistry Matters… 
TT Loaded Microsphere 
20:80 copolymer 50:50 copolymer 
Wilson Weldter et al 2006 
Project Goal 
 Develop and assess polyanhydride nanoparticles 
as an intracellular antibiotic delivery vehicle. 
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I tracellular E ficacy of PA nanospheres encapsulated w/22% Dox ycline, 
against B. melitensis in RA S, 48 Hrs Post-treatment 
* 
* p < 0.05c 
Results 
•Encapsulated PA nanoparticles were effective 
•Depot 
•Controlled release 
•Reduced/eliminated bacterial load 
•20:80 CPH:SA more effective after 24HRS 
•20:80 CPTEG:CPH more effective after 48 HRS, with no 
viable CFU 
Key Observation 
•At later time points, the number 
of cells containing nanoparticles 
decreased with infected cells 
•Within the phagosome, there 
was limited colocalization 
between nanoparticles and 
Brucella. 
•Nanoparticles and/or Brucella 
were not always localized within 
the phagosome 
 
 
 
 
  
 Incorporate encapsulated & blank nanoparticles in In vitro 
Brucella killing assay. 
Hypothesis 
 1. Colocalization between Brucella and NPs (antibiotics + 
dye), would not occur, as the NP arrive at their depot and 
releasing antibiotic, which kills Brucella, overtime and 
eliminating any GFP fluorescence. 
  
 2. Colocalization between Brucella and NP (dye alone), 
would occur, as the NPs arrive at their depot but do not 
contain antibiotic. Allowing Brucella to survive and 
fluoresce GFP. 
Brucella melitensis in RAW 264.7 CELLS, 72 HRS P.I. 
 Colocalization of B. melitensis (GFP) and LAMP-1 (Cy5) 
ROI Area (pixels^2) Pearson's Coeff. Overlap Overlap Index 1 Overlap Index 2 Coloc. Index 1 Coloc. Index 2 
Entire Slice 1.0486E+06 0.43717 0.64569 0.88946 0.46873 0.12342 0.02395 
Brucella melitensis in RAW 264.7 CELLS, 2 HRS P.T. (CC) 
 Colocalization of B. melitensis (GFP) and LAMP-1 (Cy5) 
ROI Area (pixels^2) Pearson's Coeff. Overlap Overlap Index 1 Overlap Index 2 Coloc. Index 1 Coloc. Index 2 
Entire Slice 1.0486E+06 0.19947 0.675457 0.29038 1.5725 0.0025612 0.011465 
Brucella melitensis in RAW 264.7 CELLS, 24 HR P.T. (CC) 
 Colocalization of B. melitensis (GFP) and Nanoparticles with Antibiotic (Rhod-B) 
ROI Area (pixels^2) Pearson's Coeff. Overlap Overlap Index 1 Overlap Index 2 Coloc. Index 1 Coloc. Index 2 
Entire Slice 6.40E+05 0.45195 0.93573 0.87632 0.99917 0 0.0099362 
Brucella melitensis in RAW 264.7 CELLS, 24 HR P.T. (CCB) 
 Colocalization of B. melitensis (GFP) and Nanoparticles without Antibiotic (Rhod-B) 
ROI Area (pixels^2) Pearson's Coeff. Overlap Overlap Index 1 Overlap Index 2 Coloc. Index 1 Coloc. Index 2 
Entire Slice 6.40E+05 0.68038 0.86893 1.2357 0.61101 0.0062776 0.027314 
Brucella melitensis in RAW 264.7 CELLS, 24 HR P.T. (CS) 
 Colocalization of B. melitensis (GFP) and Nanoparticles with Antibiotic (Rhod-B) 
ROI Area (pixels^2) Pearson's Coeff. Overlap Overlap Index 1 Overlap Index 2 Coloc. Index 1 Coloc. Index 2 
Entire Slice 6.40E+05 0.46532 0.92486 0.94313 0.90694 0.00066127 0.0043028 
Brucella melitensis in RAW 264.7 CELLS, 24 HR P.T. (CSB) 
 Colocalization of B. melitensis (GFP) and Nanoparticles without Antibiotic (Rhod-B) 
ROI Area (pixels^2) Pearson's Coeff. Overlap Overlap Index 1 Overlap Index 2 Coloc. Index 1 Coloc. Index 2 
Entire Slice 6.40E+05 0.94981 0.98905 1.0748 0.91019 0.026637 0.017083 
Results 
•At 24 hours post treatment blank nanoparticles 
(CCB/CSB) had significantly larger Pearson Coefficients 
compared to (CC/CS) 
•20:80 CCB Pearson Coefficient Average (0.713) 
•20:80 CSB Pearson Coefficient Average (0.927) 
Key Observation 
•Although nanoparticles were 
observed in phagosome, many 
were outside of cells, sometimes 
causing a lot of background in 
microscopy images 
  
Key Observation 
•With microscopy, there was 
difficulty quantifying 
monolayer sub-population 
(High-Low-No Infection) 
•Difficulty gating populations 
  
T = 96 
Imagestream 
UTILIZING MULTI-SPECTRAL IMAGING FLOW CYTOMETRY TO 
QUANTIFY THE INTERNALIZATION/COLOCALIZATION OF 
POLYANHYDRIDE NANOPARTICLES OR BACTERIA IN RAW 264.7 CELLS  
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20:80 CPTEG:CPH 
ImageStream Significance 
 IS capable of detecting both internalized nanoparticles as 
well as bacteria, and excluding external components 
 IS capable of gating and generating robust statistical data 
about subpopulations within an infection profile. 
 IS capability provides an accurate cell-by-cell analysis of 
fluorescent signal intensities and spatial relationships 
(colocalization) between different structures and cellular 
features at high speed.  
Conclusions 
•Encapsulated PA nanoparticles are effective 
therapeutic agents capable of reducing/eliminating 
bacterial load in murine macrophages. 
•PA nanoparticles localize in phagosomal compartments 
•PA nanoparticles safely deliver antigen 
•PA nanoparticles can control release of antigen 
•PA nanoparticles chemistry modifications alter 
therapeutic profile 
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B. pseudomallei T = 24 PT  
with NP doxycycline 
Future Directions: Burkholderia spp. 
 
* 
* p < 0.05c 
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